Solventum (NYSE:SOLV) Issues FY 2025 Earnings Guidance

Key Points

• Solventum (NYSE:SOLV) has issued FY 2025 earnings guidance with EPS projected between 5.800 and 5.950, surpassing the consensus estimate of 5.577.
• Stock analysts have shown positive sentiment, with Argus and Morgan Stanley upgrading Solventum's stock ratings, resulting in target prices raised to $90.00 and $103.00 respectively.
• Despite the positive outlook, Solventum's stock has experienced a slight decline of 0.8%, currently trading at $71.99.

Solventum (NYSE:SOLV - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 5.800-5.950 for the period, compared to the consensus EPS estimate of 5.577. The company issued revenue guidance of -.

Wall Street Analysts Forecast Growth

SOLV has been the topic of several research analyst reports. Argus raised shares of Solventum from a "hold" rating to a "buy" rating and set a $90.00 target price on the stock in a research report on Tuesday, July 1st. Morgan Stanley upgraded Solventum from an "equal weight" rating to an "overweight" rating and upped their price objective for the stock from $80.00 to $103.00 in a report on Tuesday, July 15th. KeyCorp started coverage on Solventum in a report on Friday, June 6th. They issued a "sector weight" rating on the stock. Finally, Piper Sandler upgraded Solventum from a "neutral" rating to an "overweight" rating and upped their price target for the stock from $78.00 to $87.00 in a research note on Monday, May 19th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Solventum presently has an average rating of "Hold" and an average target price of $84.38.

Solventum Stock Down 0.8%

Solventum stock traded down $0.58 during midday trading on Thursday, hitting $71.99. 1,313,737 shares of the stock were exchanged, compared to its average volume of 602,358. Solventum has a 1 year low of $55.62 and a 1 year high of $85.92. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.19 and a quick ratio of 0.85. The firm has a market cap of $12.45 billion, a P/E ratio of 13.29, a P/E/G ratio of 1.86 and a beta of 0.52. The company has a 50 day moving average price of $74.21 and a two-hundred day moving average price of $73.02.

Solventum (NYSE:SOLV - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $1.69 EPS for the quarter, topping the consensus estimate of $1.45 by $0.24. Solventum had a return on equity of 31.01% and a net margin of 4.55%. During the same period in the previous year, the business earned $1.56 EPS. The business's revenue was up 3.8% on a year-over-year basis. On average, sell-side analysts predict that Solventum will post 6.58 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Solventum

A number of institutional investors have recently modified their holdings of the stock. United Services Automobile Association bought a new position in Solventum in the 1st quarter worth approximately $239,000. Woodline Partners LP boosted its stake in Solventum by 40.7% in the 1st quarter. Woodline Partners LP now owns 11,677 shares of the company's stock worth $888,000 after purchasing an additional 3,377 shares during the period. Finally, Intech Investment Management LLC raised its position in Solventum by 167.0% during the first quarter. Intech Investment Management LLC now owns 16,669 shares of the company's stock valued at $1,268,000 after buying an additional 10,425 shares during the period.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.